Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $41.23 in the prior trading day, Janux Therapeutics Inc (NASDAQ: JANX) closed at $40.60, down -1.53%. In other words, the price has decreased by -$1.53 from its previous closing price. On the day, 1.22 million shares were traded. JANX stock price reached its highest trading level at $42.06 during the session, while it also had its lowest trading level at $40.431.
Ratios:
Our goal is to gain a better understanding of JANX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 62.09 and its Current Ratio is at 62.09. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on May 30, 2024, initiated with a Sector Perform rating and assigned the stock a target price of $47.
On March 21, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $62.
On March 20, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $100.Cantor Fitzgerald initiated its Overweight rating on March 20, 2024, with a $100 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 03 ’24 when Lichter Jay sold 1,500,000 shares for $54.75 per share. The transaction valued at 82,125,000 led to the insider holds 633,673 shares of the business.
Reardon Tighe sold 822,721 shares of JANX for $45,043,975 on Jun 03 ’24. The Acting Chief Financial Officer now owns 633,673 shares after completing the transaction at $54.75 per share. On Jun 03 ’24, another insider, Avalon Ventures XI, L.P., who serves as the 10% Owner of the company, sold 822,721 shares for $54.75 each. As a result, the insider received 45,043,975 and left with 633,673 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2129664768 and an Enterprise Value of 1509987072. For the stock, the TTM Price-to-Sale (P/S) ratio is 288.77 while its Price-to-Book (P/B) ratio in mrq is 3.21. Its current Enterprise Value per Revenue stands at 207.217 whereas that against EBITDA is -21.32.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $65.60, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is -7.28%, while the 200-Day Moving Average is calculated to be 43.68%.
Shares Statistics:
The stock has traded on average 777.31K shares per day over the past 3-months and 556130 shares per day over the last 10 days, according to various share statistics. A total of 46.25M shares are outstanding, with a floating share count of 35.22M. Insiders hold about 32.07% of the company’s shares, while institutions hold 73.25% stake in the company. Shares short for JANX as of 1721001600 were 3676569 with a Short Ratio of 4.73, compared to 1718323200 on 2874621. Therefore, it implies a Short% of Shares Outstanding of 3676569 and a Short% of Float of 14.099999999999998.
